Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of
Oncology Research ISSN: 2643-4563

Citation

Nasr F, Al Ghoche A, Diab S, Maddah J, Mansour L, et al. (2018) Pembrolizumab Monotherapy in Relapsed Hepatocellular Carcinoma Post Living Donor Liver Transplantation and Sorafenib. Int J Oncol Res 1:009. doi.org/10.23937/ijor-2017/1710009

Copyright

© 2018 Nasr F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CASE REPORT | OPEN ACCESS DOI: 10.23937/ijor-2017/1710009

Pembrolizumab Monotherapy in Relapsed Hepatocellular Carcinoma Post Living Donor Liver Transplantation and Sorafenib

Fadi Nasr1,2*, Ahmad Al Ghoche1, Saada Diab1, Janah Maddah1, Layal Mansour1, Ali kassem1 and Abd El Karim Gheith1

1Hematology-Oncology Department, Mount Lebanon Hospital, Beirut, Lebanon

2Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Abstract

Background

Despite of the high incidence of hepatocellular carcinoma (HCC), treatment strategies stays restrained. New treatment aspects remain a necessity to improve overall survival of patients.

Case report

Here, we report for the first time a 2 years complete remission of hepatocellular carcinoma with pembrolizumab after failure of sorafenib and progression after liver transplantation.

Conclusion

Immunotherapy became a field of interest in HCC for researchers and clinicians in order to establish new immunotherapy modalities that improve response to treatment of HCC.